| (Values in U.S. Thousands) | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 | Dec, 2011 |
| Sales | 700 | 0 | 14,730 | 12,550 | 8,180 |
| Sales Growth | unch | -100.00% | +17.37% | +53.42% | -82.50% |
| Net Income | -52,190 | -41,840 | -38,620 | -44,330 | -42,040 |
| Net Income Growth | -24.74% | -8.34% | +12.88% | -5.45% | -19.94% |
Epirus Biopharm Inc (EPRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
EPIRUS Biopharmaceuticals Inc. is a biopharmaceutical company. It is focused on the development and commercialization of biosimilar monoclonal antibodies. Its products include BOW015, a monoclonal antibody against tumor necrosis factor alpha, used to treat autoimmune diseases. EPIRUS Biopharmaceuticals Inc., formerly known as Zalicus Inc., is based in Boston, Massachusetts.